SK Biopharm (326030) financial statements

+64223.0%since 2018
FY2025 revenue
₩706.7B▲ +29.1%
FY2025 net income
₩267.0B▲ +10.9%
FY2025 diluted EPS
₩3,409.00▲ +10.9%
FY2025 free cash flow
₩169.4B▲ +81.2%

SK Biopharm income statement

SK Biopharm income statement
KRW millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Revenue706,741547,596354,892
Gross profit663,840504,495320,809
Operating income203,93896,340-37,522
Pretax income150,88472,596-43,858
Net income266,950240,738-32,883
Diluted earnings per share3,409.003,074.00-420.00

SK Biopharm balance sheet

SK Biopharm balance sheet
KRW millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Cash and cash equivalents307,771322,807239,700
Total assets1,198,3091,036,811723,171
Total liabilities372,039462,827402,219
Total equity826,270573,984320,951
Long-term debt0094,484

SK Biopharm cash flow statement

SK Biopharm cash flow statement
KRW millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Operating cash flow176,33494,900-94,201
Capital expenditure-6,892-1,395-2,385
Free cash flow (derived)169,44293,505-96,586

Quarterly highlights

Quarterly highlights
KRW millionsQ3 FY2026Q2 FY2026Q1 FY2026Q4 FY2025
Period ended30 Sep 202630 Jun 202631 Mar 202631 Dec 2025
Revenue (derived)258,418247,367227,886194,360
Operating income (derived)116,28397,06489,76846,278
Net income (derived)54,34185,065105,162136,593
Diluted earnings per share694.001,086.001,343.00n/a
Operating cash flow (derived)95,01678,14817,91887,004
Total assets1,395,1661,418,7651,320,4211,198,309

SK Biopharm major shareholders

SK Biopharm major shareholders
HolderShare of classSharesFiled
SK50.1%39,268,67130 March 2026
국민연금공단6.0%4,697,03531 March 2026

SK Biopharm DART filings

SK Biopharm DART filings
FiledFormType
15 November 2026Quarterly ReportQuarterly report
25 August 2026Major Matters ReportCurrent report
13 August 2026Semiannual ReportHalf-year report
14 May 2026Quarterly ReportQuarterly report
17 March 2026Business ReportAnnual report
13 November 2025Quarterly ReportQuarterly report
13 August 2025Semiannual ReportHalf-year report
14 May 2025Quarterly ReportQuarterly report

Common questions

What was SK Biopharm's revenue in fiscal 2025?

SK Biopharm reported ₩706.7 billion in revenue for fiscal 2025, the year ended 31 December 2025, up 29.1% from fiscal 2024.

What was SK Biopharm's net income in fiscal 2025?

SK Biopharm reported net income of ₩267.0 billion for fiscal 2025, the year ended 31 December 2025, up 10.9% from fiscal 2024. Diluted earnings per share were ₩3,409.00.

What was SK Biopharm's free cash flow in fiscal 2025?

SK Biopharm had ₩169.4 billion in free cash flow in fiscal 2025. Operating cash flow was ₩176.3 billion and capital expenditure was ₩6.9 billion.

What were SK Biopharm's total assets at the end of fiscal 2025?

SK Biopharm reported total assets of ₩1.2 trillion at the end of fiscal 2025, the year ended 31 December 2025.

How much SK Biopharm history do I get?

Every account gets the full history, annual and quarterly, with first reported values and as of dates.